Pelago Bioscience enable successful Drug Discovery by providing physiologically relevant high quality Target Engagement data using the patented CETSA® method. We combine extensive commercial Drug Discovery experience with world leading fundamental basic scientific research.
Our focus is to deliver high quality target engagement data to our customers and partners, enabling faster development of better and more efficacious new drugs. By outsourcing your Target Engagement assays to us you reduce your risk and speed up project progression. We provide a flexible fee for service model and can also offer method sublicensing, tech transfer as well as consulting and risk shared collaborations.
Target engagement of a drug is pivotal to efficacy. In spite of this fact, target engagement (TE) is often only measured at very late stages of the drug discovery value chain. It is well established that insufficient TE lead unequivocally to insufficient efficacy. Likewise, more than half, 59% of all candidate drugs fail at the proof of concept stage in clinical trials.
The Cellular Thermal Shift Assay (CETSA®) gives a quantitative measure of target engagement. With no modifications of target or compounds, CETSA® delivers a true physiological relevant biophysical readout of affinity, adding real value to existing efficacy assays. We provide a measure for TE, which will help you make the right decisions faster and improve the quality in your discovery programmes.
Pelago Bioscience AB has not received any reviews.
Pelago Bioscience AB has not received any endorsements.